Roflumilast (Daxas)

Executive summary

Chronic obstructive pulmonary disease (COPD) remains a significant area of unmet medical need. It is a progressive and irreversible lung disease that restricts breathing. 

Daxas (Roflumilast) is a phosphodiesterase-4 (PDE4) inhibitor that is being developed to treat the underlying inflammation in COPD and related inflammatory diseases. It could be both the first PDE4 inhibitor and the first orally administered anti-inflammatory treatment for COPD patients. As a once-daily, non-steroidal anti-inflammatory treatment, Daxas offers the opportunity for a new approach to the treatment of COPD.

 

 

Table of content

I. Presentation - General Information

II. Asthma and Chronic Obstructive Pulmonary Disease (COPD)
Market Analysis
Treatment Trends
New Treatments For COPD
Phosphodiesterase inhibitors

III. Originators - In-Licensers - Partners
Originators 
In-Licensers
Partners

IV. Regulatory

V. Clinical Trials

VI. SWOT Analysis

VII. News

 

 

Publication date: Number of pages: Price:
2009-11-25 24 1500 euros